Kevin Li

Kevin Li is currently a Senior Research Associate at R2M Pharma. Prior to that, they were a Senior Scientist at Connora Technologies from September 2015 to August 2018 where they worked on synthesis and process development of small molecules. Kevin has also worked as an organic chemist at Light Polymers from July 2012 to July 2014 where they were responsible for synthesis and process development of polymers (lyotropic liquid crystals). Kevin Li started their professional career as a Senior Research Scientist - Medicinal Chemistry at Curia (formerly AMRI) from January 2001 to December 2011 where they were responsible for synthesizing target molecules for clients in medicinal chemistry projects. Kevin also synthesized the clinical candidate "Liafensine" (Phase II for treatment of depression) during their time at Curia. Kevin Li has 3 publications and 1 chapter in a "Heterocycles in Organic Synthesis".

Kevin Li has a PhD in Organic Chemistry from McGill University. Kevin did their post-doctoral work in organic synthesis at Leibniz Universität Hannover. Kevin has an MSc in Chemistry from the Indian Institute of Technology, Delhi. Kevin also has certifications from Coursera in Introduction to Biology of Cancer and Davidson College in Medicinal Chemistry.

Kevin Li works with and Ulhas Bhatt - Principal Scientist. Kevin Li reports to Julio Medina, Founder & CEO.